Berlin Cures Reaches Key Milestone in Phase II Trial for Long COVID Treatment

Berlin Cures, a clinical-stage biotechnology company, is making significant progress in its Phase II trial targeting Long COVID, with over half of the necessary patient recruitment completed. The trial focuses on BC 007, an aptamer-based drug designed to neutralize pathogenic functional autoantibodies (fAABs), which are believed to contribute to the persistence of Long COVID symptoms. This development marks a crucial step in addressing Long COVID, a condition affecting over 100 million people worldwide.

The Europe-wide clinical trial has successfully enrolled more than 50% of its target of 114 patients and is ongoing across multiple centers in Finland, Germany, Austria, Switzerland, and Spain. With plans to expand the trial even further, Berlin Cures highlights the collaborative effort required to tackle the global health issue of Long COVID. Interim results expected in autumn 2024 could facilitate the transition to the pivotal Phase III study, essential for regulatory approval of BC 007.

Dr. Oliver von Stein, CEO of Berlin Cures, emphasizes the urgency of addressing Long COVID, citing the detriment to people's quality of life and the broader economic and social impact. Berlin Cures' strategy aims not only at finding a viable treatment for Long COVID but also explores BC 007's potential in tackling various autoimmune diseases by neutralizing harmful fAABs. The biotech firm continues its efforts to secure additional funding for the crucial next stages of development.